{{Rsnum
|rsid=11622887
|Gene=C14orf49
|Chromosome=14
|position=95476110
|Orientation=plus
|GMAF=0.4867
|Gene_s=C14orf49
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;C)
| geno3=(C;C)
| CEU | 29.2 | 48.7 | 22.1
| HCB | 32.8 | 45.3 | 21.9
| JPT | 29.5 | 44.6 | 25.9
| YRI | 8.2 | 39.5 | 52.4
| ASW | 15.8 | 49.1 | 35.1
| CHB | 32.8 | 45.3 | 21.9
| CHD | 31.2 | 49.5 | 19.3
| GIH | 18.8 | 47.5 | 33.7
| LWK | 17.3 | 40.9 | 41.8
| MEX | 44.8 | 44.8 | 10.3
| MKK | 18.6 | 44.2 | 37.2
| TSI | 32.4 | 47.1 | 20.6
| HapMapRevision=28
}}{{PMID Auto GWAS
  |PMID=23478653
  |Trait=Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer
  |Title=A genome-wide association study of survival in small-cell lung cancer patients treated with irinotecan plus cisplatin chemotherapy.
  |RiskAllele=
  |Pval=3E-7
  |OR=3.50
  |ORtxt=[2.20-5.60]
  }}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Illumina Human 1M}}